{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T11:31:15Z","timestamp":1648899075648},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.medcli.2014.09.008","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T00:55:03Z","timestamp":1416531303000},"page":"65-66","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interfer\u00f3n \u00df, microangiopat\u00eda tromb\u00f3tica y s\u00edndrome nefr\u00f3tico"],"prefix":"10.1016","volume":"144","author":[{"given":"Luis F.","family":"Quintana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M.","family":"Campistol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2014.09.008_bib0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12195","article-title":"The role of type i interferons in intestinal infection, homeostasis, and inflammation","volume":"260","author":"Cho","year":"2014","journal-title":"Immunol Rev."},{"key":"10.1016\/j.medcli.2014.09.008_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000057631","article-title":"Immune-mediated complications during interferon therapy in hematological patients","volume":"107","author":"Raanani","year":"2002","journal-title":"Acta Haematol."},{"key":"10.1016\/j.medcli.2014.09.008_bib0015","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2014.09.008_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2011.09.032","article-title":"Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis","volume":"313","author":"Feng","year":"2012","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.medcli.2014.09.008_bib0025","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2215\/CJN.07311009","article-title":"Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis","volume":"5","author":"Markowitz","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2014.09.008_bib0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ajpath.2013.04.017","article-title":"The antiviral cytokines IFN-\u03b1 and IFN-\u03b2 modulate parietal epithelial cells and promote podocyte loss: Implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration","volume":"183","author":"Migliorini","year":"2013","journal-title":"Am J Pathol."},{"key":"10.1016\/j.medcli.2014.09.008_bib0035","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2014.09.008_bib0040","first-page":"329","article-title":"Delay in growth and the development of nephritis in rats treated with interferon preparations in the neonatal period","volume":"95","author":"Gresser","year":"1979","journal-title":"Am J Pathol."},{"key":"10.1016\/j.medcli.2014.09.008_bib0045","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1681\/ASN.2004111014","article-title":"Interferon-beta: A therapeutic for autoimmune lupus in MRL-Faslpr mice","volume":"16","author":"Schwarting","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2014.09.008_bib0050","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: A phase i randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2014.09.008_bib0055","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1053\/j.ajkd.2012.11.049","article-title":"Nephrotic syndrome in a multiple sclerosis patient receiving long-term interferon beta therapy","volume":"61","author":"Wallbach","year":"2013","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.medcli.2014.09.008_bib0060","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","author":"Hunt","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2014.09.008_bib0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11255-013-0401-7","article-title":"Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis","volume":"46","author":"Orvain","year":"2014","journal-title":"Int Urol Nephrol."},{"key":"10.1016\/j.medcli.2014.09.008_bib0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/IJNRD.S30194","article-title":"Thrombotic microangiopathy associated with use of interferon-beta","volume":"5","author":"Olea","year":"2012","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"10.1016\/j.medcli.2014.09.008_bib0075","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/DDDT.S42138","article-title":"Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis","volume":"7","author":"Mahe","year":"2013","journal-title":"Drug Des Devel Ther."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775314007003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775314007003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T15:25:46Z","timestamp":1538061946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775314007003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0025775314007003"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2014.09.008","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interfer\u00f3n \u00df, microangiopat\u00eda tromb\u00f3tica y s\u00edndrome nefr\u00f3tico","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2014.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}